Clinical Trial Update: Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis. [Phase 2]

View source ↗

Summary

Phase 2 trial update for jaktinib hydrochloride tablets in intermediate- and high-risk myelofibrosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Jaktinib hydrochloride tablets (Jaktinib hydrochloride)

Snippet

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Conditions: Myelofibrosis | Phase 2 | Status: COMPLETED